Mahshid Ghasemi, Former Research Scientist in Oncology Nanomedicine at University of South Australia, shared a post on LinkedIn:
“I recently completed an online course delivered by the European School of Oncology to update my knowledge on oncology research and clinical trials.
I really enjoyed the insightful presentations by the speakers, covering a wide range of topics, with a focus on the latest advancements in cancer research from bench to bedside:
Novel approaches in cancer research and diagnostics
• Integrative morpho-molecular pathology
• Personalized oncology
• Consideration of spatial (Intratumor, intrapatient) and temporal tumor heterogeneity in tumor classification.
• Genomics, transcriptomics, epigenomics, proteomics, metabolomics, and radiomics
• Single-cell and spatial omics
• Multi-omics integration and tumor molecular signature
• Multiplex and next-generation IHC
• Liquid biopsy
• ctDNA and MRD (minimal residual disease) testing
• TME (Tumor microenvironment) and cancer immunity analysis
• Digital pathology and AI-based diagnostics (multiomics integration, predicting genomic alterations based on H&E, ethical and legal considerations, …)
• Multidisciplinary molecular tumor boards
Oncology preclinical research
• Drug design and screening (high-throughput screening, drug combination screening)
• Preclinical models (2D and 3D cell culture, animal & patient-derived models, organoids)
• Cancer resistance models
• Live-cell imaging applications
Oncology clinical trials
• Objectives and endpoints in oncology clinical trials (phases I-III)
• Novel approaches to dose definition and optimization
• Patient-centered trial design
• Novel and biomarker-driven trial designs (Seamless, Adaptive, Basket, Umbrella)
• In silico models for trial design
• Statistical considerations in oncology trial design, from sample size determination and SAP (statistical analysis plans) to data visualization
• Considerations in drafting an oncology trial protocol
Notably, the speakers highlighted the importance of multidisciplinary and cross-sector collaboration across academia, industry, and clinical practice to increase the success rate in oncology drug development.
I highly recommend this free two-day self-paced course to anyone interested in oncology research. Participants will be issued a certificate of attendance after completing a learning assessment test.
Here is the link to the online course.”
More posts featuring European School of Oncology.